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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idThe Ebola Virus Diseases, EVD, epidemic is still unfolding in
West Africa with Guinea, Sierra Leone and Liberia most severely
affected. This week it was estimated that there is at least 500 new
cases every week and the total number of cases has passed 16,000,
but there is probably a substantial underreporting of both cases
and fatalities.1 There are some doubts about the mortality rate, but
one recent case series reported a mortality of 72%.2
The outbreak is unprecedented in magnitude and few would
have predicted that such an outbreak was possible. However, it
seems clear that it is not due to a more pathogenic version of the
Ebola virus and indeed low virus genetic diversity has been
observed in person-to-person virus transmission.3,4 Therefore, the
current situation is most probable due to the poor status of the
health care systems especially in Liberia and Sierra Leone, which
has both recently suffered long civil wars, which have left the
countries drained for educated health care staff and a dilapidated
health infrastructure.
There is no approved, speciﬁc treatment of EVD. Several
experimental anti-virals, immune-therapy5 and use of hyperim-
mune plasma from survivors have been proposed, but data from
controlled clinical trials are lacking.6
After a slow start the international community including many
Non Governmental Organizations, NGO’s, are managing treatment
facilities in West Africa
But what are these treatment facilities offering?
Very little data has emerged. One published study reported a
mortality of 72% but astonishingly the study contained no
information of any treatment.2 Thus the question remains if the
patients included in that study received any treatment at all. These
patients were all from Sierra Leone and in contrast, nationals
from industrialized countries are evacuated and treated in their
home country and survived.7,8 In particular, the case evacuated
to Germany7 show very clearly that the treatment with classical
tools used for patients in severe chock (bacterial septicemia, severe
malaria) is expected to substantially reduce mortality. The patients
received 30 liters of ﬂuid intravenously over the ﬁrst three days,
had paralytic ileus and thus could not take oral ﬂuid, had an fecal
output of 14 liters over three days and severe hypokalemia. The
same problems were seen in the two patients evacuated to the
United States and one of these also had malaria.8
Is this a proper level of inpatient care in the Ebola treatment
facilities or should we aim higher?
A mortality of 43% were reported in a case series of 80 patients
with EVD from Guinea where 76% of the patients receivedhttp://dx.doi.org/10.1016/j.ijid.2014.12.002
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).intravenous ﬂuid even though only 1 titer over 24 hours in
average.9 If the difference in mortality between the report from
Sierra Leone (72%)2 and Guinea (43%)9 are due to the use of
intravenous ﬂuid and even though one liter intravenous ﬂuid
seems very modest in view the need in the three expatriated
cases7,8, it seems that intravenous ﬂuid replacement may
signiﬁcantly reduce mortality in the treatment centers perhaps
by as much as 50%. This can be done in the conditions prevailing in
West Africa using pulse, blood pressure, body weight and urine
output as guidance and using simple point-of-care tests for
measuring electrolytes, but require intravenous access, abundant
ﬂuid for intravenous administration and trained staff.
It is telling that the NGO’s have not published any treatment
results and it is unclear if there is any control of treatment
outcomes in EVD treatment facilities. Simply notifying conﬁrmed
cases and outcomes (fatal or not) and publishing weekly updates
broken down to different NGO’s would allow quality control and
allow adjustment of treatment algorithms adopting procedures
identifying the highest survival rates. The difference in mortality
between the two published case series2,9 indicate that this is
urgently needed.
We must to ensure that treatment is not palliation and that the
so-called ‘‘Ebola hospitals’’ are hospitals and not hospices for
untreated cases with the sole purpose of isolating cases from the
community.
It is estimated in a study from Liberia, that only 25% of known
Ebola patients had been admitted to an Ebola treatment facility as
of August 14, 2014.10 The reasons for this low number are many,
but a key point is probably that the chance of survival in these units
does not differ signiﬁcantly from patients staying at home.
The national governments in the affected countries does not
have the resources nor the manpower to ensure the quality of
the care provided by NGO’s and others. Thus the World Health
Organization or others with the necessary resources should
establish a notiﬁcation system, to ensure that facilities are
providing treatment and not only palliation and publish for
instance weekly updates of survival ﬁgures broken down for each
NGO to ensure quality control, transparency and optimization
of treatment algorithms.
The German patient7 had septicemia and one of the American
patients had malaria.8 Both diagnosis can lead to disseminated
intravascular coagulation and will thus easily be confused with
Ebola. If diagnostics are not available perhaps every patients in this
highly endemic malaria area should receive a malaria treatmentciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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ceftriaxone.
It is important to know if a patient is HIV positive as a low CD4
T cell count is expected to increase the risk of a fatal outcome,
and thus treatment efﬁcacy if at all possible should be stratiﬁed
according to HIV status.
It is urgently needed to develop guidelines for treatment of
EVD patients and to distinguish treatment from palliation and
hospitals from hospices.
We suggest that the World Health Organization take the
leadership and develop guidelines for treatment including:
1. Diagnosis of EVD
2. Principles for intravenous ﬂuid replacement
3. Principles for measurement of electrolyte imbalance
4. Principles for correction of electrolyte imbalance
5. Diagnosis and treatment of concomitant malaria
6. When to administer antibiotics based on suspicion of septicemia
7. HIV testing.
8. Implement a reporting system for all EVD treatment facilities
These measures can all be implemented under the ﬁeld
conditions in West Africa, provided the staff are trained in high
volume ﬂuid replacement. Participating should be a prerequisite
for receiving ﬁnancial support from governments and receiving
permission to manage EVD treatment facilities.
The stafﬁng of the treatment facilities is a crucial issue and it
can be speculated that the NGO’s does not have access to
physicians and nurses with knowledge and experience in high
volume ﬂuid replacement and correction of electrolyte imbalance.
One solution could be twinning with hospitals in industrialized
countries where these hospitals adopt an EVD treatment facility
and ensure stafﬁng and training. This of course would need support
from the national health authorities. Such a program would ensure
effective intravenous ﬂuid replacement therapy were preovided,
most probably signiﬁcantly reduce mortality, ensure conﬁdence in
the treatment facilities from the local population and thus increase
the use of these facilities (earlier admission and higher proportion
of cases treated, isolated and recovered).
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